|
|
News Breaks | | | | February 19, 2013 | | 06:12 EDT |  | BCRX | BioCryst sees FY13 net operating cash use $22M-$26M
Based upon current trends and assumptions, as well as the Company's restructured operations, BioCryst expects FY13 operating expenses to be in the range of $25M-$35M. | |
|
News For BCRX From The Last 14 Days Check below for free stories on BCRX the last two weeks. |
|
|
| There are no results for BCRX |
|
|
|
|
|
|
